Joel Schlessinger M.D.

Joel Schlessinger MD was recently elected a member of the Noah Worcester Dermatological Society by the Board of Trustees. Joel Schlessinger is honored to receive this prestigious membership. The Noah Worcester Dermatological Society is a small national dermatological organization that is characterized by a number of scientific programs. Membership is selectively limited in order to […]

An FDA-approved formulation of botulinum neurotoxin type A has been used in the treatment of moderate to severe glabellar lines. Dr. Joel Schlessinger analyzed the long-term safety data of this injection in his article, “An analysis of the long-term safety data of repeat administrations of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.” […]

Botulinum toxin type A has been proven to be a safe and effective one-time treatment for minimizing glabellar lines. Dr. Joel Schlessinger and colleagues administered a study to discover if repeated treatment of botulinum toxin type A has long-term efficacy and tolerability. This study, “The efficacy and safety of a new U.S. Botulinum toxin type […]

Joel Schlessinger MD and colleagues administered a study evaluating the safety and efficacy of clobetasol proprionate for dermatoses in adults and adolescents. The study, “Clobetasol proprionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents,” was published in the Journal of the […]